Olanzapine, Prochlorperazine Both Alleviate Refractory Chemo-Related Nausea

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 2, 2024.

By Lori Solomon HealthDay Reporter

WEDNESDAY, Oct. 2, 2024 -- Olanzapine may be better than prochlorperazine for reducing refractory nausea in patients with breast cancer starting a high/moderate emetogenic chemotherapy regimen, according to a study presented at the American Society of Clinical Oncology annual Quality Care Symposium, held from Sept. 27 to 28 in San Francisco.

Luke Joseph Peppone, Ph.D., from the University of Rochester Medical Center in New York, and colleagues randomly assigned 310 chemotherapy-naive patients with breast cancer starting a high/moderate emetogenic chemotherapy regimen with moderate or worse nausea (≥3 on a 1-to-7 scale) in cycle 1 to olanzapine, prochlorperazine, or placebo.

The researchers found a statistically significant change in average nausea score for the olanzapine (average change, −1.07: Cohen's Δ = 0.49) and prochlorperazine groups (average change, −0.94: Cohen's Δ = 0.38) versus the placebo group (average change, −0.50). For change in maximum nausea score, similar but larger changes were seen in the olanzapine (maximum change, −2.57: Cohen's Δ = 0.86) and prochlorperazine arms (maximum change, −2.01: Cohen's Δ = 0.47) versus the placebo arm (maximum change, −1.30). From before chemo to cycle 2, the olanzapine group had a clinically significant change in overall quality of life compared with the placebo group (Functional Assessment of Cancer Therapy-General [FACT-G] mean difference, +4.91). However, the prochlorperazine arm did not have significant improvement versus placebo (FACT-G mean difference, −0.87). Olanzapine showed superiority versus prochlorperazine for changes in maximum nausea score (mean difference, −0.56) and quality of life (FACT-G mean difference, +5.80), but not for average nausea (mean difference, −0.13).

"This study fills the gap in empirical comparisons and solidifies olanzapine's position as a promising intervention for refractory nausea," the authors write.

Several authors disclosed ties to the pharmaceutical industry.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-03 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords